Overview

A Study of Obexelimab in Patients With Systemic Lupus Erythematosus

Status:
RECRUITING
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).
Phase:
PHASE2
Details
Lead Sponsor:
Zenas BioPharma (USA), LLC